argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026

Key Takeaways

• argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters.
• New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP).
• argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS).

argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials.

In MG, the company will present three sets of findings:

• Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.
• Anti-AChR antibody-negative gMG. One-year ADAPT SERON results show sustained efficacy and consistent safety, with mean MG-ADL improvements of about 5 points maintained through Week 52. A German registry analysis found higher disease burden in patients without detectable anti-AChR antibodies, with a mean MG-ADL score of 6.9 versus 4.8 in antibody-positive patients.
• Earlier treatment. A real-world analysis of more than 1,100 U.S. patients showed improvements in MG-ADL scores, steroid burden, and exacerbation rates across all sub-cohorts, with the greatest gains in patients who started earlier. Patients treated within a year of diagnosis had a mean MG-ADL reduction of 4.7 points over the first three months, versus 3.5 points for those treated more than three years after diagnosis.

In CIDP, an interim analysis of the ADHERE and ADHERE+ studies followed patients beyond five years of treatment with VYVGART Hytrulo, and about 40% of responding participants reached an INCAT disability score of 0 or 1. A post hoc analysis found a 71.5% lower relative risk of grip strength deterioration, with early improvement detected faster by grip strength than by established disability measures. In a longitudinal analysis of treatment-naïve patients, 87.5% achieved confirmed clinical improvement. In a Phase 4 switch study, 87% of patients who started VYVGART Hytrulo one week after their last IVIg dose remained on it through 12 weeks.

The pipeline data include Phase 2 ARDA+ results showing sustained clinical benefit and consistent safety with empasiprubart in MMN. Empasiprubart is an antibody that binds C2 and blocks the classical and lectin complement pathways. argenx will also report results from a Phase 1b study of adimanebart in adults with DOK7-CMS, which found improvements in walking performance measured by digital gait outcomes. Adimanebart is an antibody that activates the muscle-specific kinase MuSK to stabilize the neuromuscular junction.

The four oral presentations cover ocular MG (three at MGFA, plus an ADAPT OCULUS oral at AANEM) and ADAPT SERON. The posters will be shown in three sessions: Wednesday, September 30 from 6:15 to 6:45 p.m. ET, and Thursday, October 1 from 9:30 to 10:00 a.m. and 2:45 to 3:15 p.m. ET. VYVGART is approved for adults with gMG, and VYVGART Hytrulo is approved for gMG and CIDP. The other uses in these presentations are investigational.